港股异动 | 派格生物医药-B(02565)涨超5% 携手三方共同加速打通派达康商业化链路产品市场放量蓄势待发

智通财经07-20

智通财经APP获悉，派格生物医药-B(02565)涨超5%，截至发稿，涨5.41%，报7.01港元，报1.32亿港元。消息面上，7月17日，派格生物医药-B、上海腾瑞制药股份有限公司与阿里健康(00241)在杭州正式签署战略合作协议。三方将发挥各自在创新药研发、专业商业化及数字医疗服务领域的优势，共同推进中国原研1类创新药派达康®(通用名：维培那肽注射液)的线上可及和患者服务。根据合作安排，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2652235261?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-20 11:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652235261","market":"fut","top_or_hot":-1,"title":"港股异动 | 派格生物医药-B(02565)涨超5% 携手三方共同加速打通派达康商业化链路 产品市场放量蓄势待发","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，派格生物医药-B(02565)涨超5%，截至发稿，涨5.41%，报7.01港元，报1.32亿港元。消息面上，7月17日，派格生物医药-B、上海腾瑞制药股份有限公司与阿里健康(00241)在杭州正式签署战略合作协议。三方将发挥各自在创新药研发、专业商业化及数字医疗服务领域的优势，共同推进中国原研1类创新药派达康®(通用名：维培那肽注射液)的线上可及和患者服务。根据合作安排，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1469612.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 派格生物医药-B(02565)涨超5% 携手三方共同加速打通派达康商业化链路 产品市场放量蓄势待发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 派格生物医药-B(02565)涨超5% 携手三方共同加速打通派达康商业化链路 产品市场放量蓄势待发\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-20 11:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1469612.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，派格生物医药-B(02565)涨超5%，截至发稿，涨5.41%，报7.01港元，报1.32亿港元。消息面上，7月17日，派格生物医药-B、上海腾瑞制药股份有限公司与阿里健康(00241)在杭州正式签署战略合作协议。三方将发挥各自在创新药研发、专业商业化及数字医疗服务领域的优势，共同推进中国原研1类创新药派达康®(通用名：维培那肽注射液)的线上可及和患者服务。根据合作安排，阿里...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1469612.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"161726","symbol_name":"生物医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1469612.html","article_id":"2652235261","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652235261","pubTimestamp":1784519009,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，派格生物医药-B涨超5%，截至发稿，涨5.41%，报7.01港元，报1.32亿港元。消息面上，7月17日，派格生物医药-B、上海腾瑞制药股份有限公司与阿里健康在杭州正式签署战略合作协议。下一阶段，市场对派达康的关注重点，将由“产品能否获批”转向医院覆盖、医生处方、患者持续用药以及线上线下协同带来的放量速度。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"161726":"生物医药","399441":"生物医药","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","KCAI":"KraneShares China Alpha Index ETF","XBI":"SPDR S&P Biotech ETF","BK1161":"生物科技","BK4581":"高盛持仓","02565":"派格生物医药-B"},"translate_title":"Changes in Hong Kong stocks | Paige Biomedical-B (02565) rose by more than 5% and joined hands with three parties to accelerate the opening of the commercialization link of Paidakang. The product market is ready for momentum","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161726":1.5,"399441":1.5,"02565":1.5,"VXUS":1.5,"XBI":1.5,"KCAI":1.5},"content_text":"智通财经APP获悉，派格生物医药-B(02565)涨超5%，截至发稿，涨5.41%，报7.01港元，报1.32亿港元。消息面上，7月17日，派格生物医药-B、上海腾瑞制药股份有限公司与阿里健康(00241)在杭州正式签署战略合作协议。三方将发挥各自在创新药研发、专业商业化及数字医疗服务领域的优势，共同推进中国原研1类创新药派达康®(通用名：维培那肽注射液)的线上可及和患者服务。根据合作安排，阿里健康将依托在线问诊、处方流转、药师审核、专业配送及用药指导等全链路服务能力，拓展派达康®的线上诊疗及患者服务场景。下一阶段，市场对派达康®的关注重点，将由“产品能否获批”转向医院覆盖、医生处方、患者持续用药以及线上线下协同带来的放量速度。对于派格生物而言，此次与腾瑞制药、阿里健康达成战略合作，不仅进一步完善了派达康®的商业化版图，也释放出更加清晰的信号：随着产品差异化、全国推广网络和数字化患者入口逐步汇合，派达康®正由商业化准备阶段加速驶入真实市场验证阶段，后续放量已蓄势待发。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652235261","isCrawlerRequest":true}

港股异动 | 派格生物医药-B(02565)涨超5% 携手三方共同加速打通派达康商业化链路 产品市场放量蓄势待发

精彩评论

港股异动 | 派格生物医药-B(02565)涨超5% 携手三方共同加速打通派达康商业化链路产品市场放量蓄势待发